Clinical Significance of KIAA1199 as a Novel Target for Gastric Cancer Drug Therapy

Anticancer Res. 2019 Dec;39(12):6567-6573. doi: 10.21873/anticanres.13872.

Abstract

Background/aim: The KIAA1199 gene has been associated with cancer-cell proliferation, but its functions remain poorly studied. Here, we examined the clinical significance of the KIAA1199 mRNA levels in locally advanced gastric cancer (GC). Materials and Methods/Results: Using samples from 254 patients with stage II/III GC, we found significantly higher KIAA1199 levels in cancerous tissues compared to adjacent normal mucosa (ANM). There was no significant relationship between KIAA1199 expression and clinical features. Although overall survival rates (OSR) of patients, who underwent surgery did not correlate with KIAA1199 expression, patients who underwent adjuvant chemotherapy with S-1 and had high KIAA1199 levels displayed significantly lower OSR. KIAA1199 knock down (KIAA1199-KD) suppressed proliferation, invasiveness, and sensitivity of GC cells to 5-fluorouracil (5-FU).

Conclusion: KIAA1199 expression appears to be a promising prognostic marker in patients with locally advanced GC, who underwent postoperative adjuvant chemotherapy with S-1. KIAA1199 may represent a novel target for GC pharmacotherapy.

Keywords: KIAA1199; S-1; gastric cancer; prognostic factor.

MeSH terms

  • Aged
  • Cell Line, Tumor
  • Cell Proliferation
  • Chemotherapy, Adjuvant
  • Digestive System Surgical Procedures
  • Drug Combinations
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Hyaluronoglucosaminidase / genetics*
  • Male
  • Middle Aged
  • Neoplasm Invasiveness
  • Oxonic Acid / therapeutic use*
  • Prognosis
  • Stomach Neoplasms / genetics
  • Stomach Neoplasms / mortality
  • Stomach Neoplasms / therapy*
  • Survival Analysis
  • Tegafur / therapeutic use*
  • Up-Regulation*

Substances

  • Drug Combinations
  • S 1 (combination)
  • Tegafur
  • Oxonic Acid
  • CEMIP protein, human
  • Hyaluronoglucosaminidase